It was another rough day for the S&P/ASX 200 (INDEXASX: ^AXJO) (ASX: XJO) today, with the index losing 2.8% to 4,832 points. Further falls could put us below levels not seen in the past two years or more.

As ever, a number of stocks fell significantly further than the index today, and here’s why:

Myer Holdings Ltd (ASX: MYR) fell 5% to $1.02 on no news as the company continues to grapple with difficult trading conditions and heavy short interest. IOOF Holdings Limited (ASX: IFL) recently became a significant holder of Myer with a 5% stake, while Goldman Sachs has a significant short-selling interest in the stock. As of 9 am this morning, ASIC reports indicate that 17% of Myer’s issued shares were held for short-sell. With such high short interest, any missteps could have a heavy impact on Myer’s share price.

Myer shares are down 43% for the year.

Lifehealthcare Group Ltd (ASX: LHC) fell 6% to $2.48 as investor uncertainty over the group’s industry continues in the wake of a government investigation into the healthcare sector. Several insurers have claimed that the cost of implanting medical devices is a major source of unnecessary healthcare spending, and thus, shareholders worry Lifehealthcare could find itself on the receiving end of adverse government changes – much like those in the pathology and diagnostic imaging sectors.

(readers wanting to find out more about Lifehealthcare’s recent price fall should read this article),

Lifehealthcare shares are up just 0.3% over the past twelve months.

Impedimed Limited (ASX: IPD) lost 11% to $0.93 after the company announced it was raising funds in a manner that significantly disadvantaged existing shareholders. New shares worth A$75m will be issued to ‘sophisticated and professional investors’, at a price of $0.95 apiece, while existing shareholders will be able to subscribe for a total of A$7.5m in shares at a later date. Share prices often fall to the price new shares will be issued at, and the enormous amount of new shares Impedimed is issuing perhaps also spooked investors.

Impedimed shares are up 16% for the year.

Adacel Technologies Limited (ASX: ADA) fell 9% to $2.21 in what could be potential profit-taking after the company’s market update last week sent its share price up 20% in a single day. Since then, shares have declined roughly 10%. Adacel has been making waves with its rapid growth and soaring share price, and indeed, the company is small enough to keep growing for quite some time. However, readers will also want to be wary of how much growth is already factored into the share price.

Adacel shares are up 738% in the past twelve months.

What would YOU do if the market crashed tomorrow?

With national debt levels at an all-time high and US interest rates set to rise, some experts are predicting a market crash. Discover our Foolish experts' advice on what YOU should do in the event of a crisis -- including expert tips on how to protect YOUR portfolio.

Simply click here for your FREE copy of our newly updated report, "What to Do When the Sharemarket Crashes". Click here, it's FREE!.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Sean O'Neill owns shares of LifeHealthcare Group Limited. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.